Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ASTX727 Versus IV Decitabine in Chinese Subjects With Myelodysplastic Syndromes
NCT06091267Phase 2Active, not recruiting
- Sponsor
- Otsuka Holdings
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, cedazuridine in myelodysplastic syndrome (MDS), sponsored by Otsuka Holdings. Started Oct 2023; status: active, not recruiting.
02
Drugs
decitabinecedazuridine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06091267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091267.